版本:
中国

BRIEF-Sophiris Bio provides update on topsalysin mid-stage study

May 23 Sophiris Bio Inc

* Sophiris bio provides update on phase 2b study of topsalysin in localized prostate cancer

* Sophiris bio inc - received regulatory clearance for diluent - medium in which topsalysin is diluted

* Sophiris bio inc - clinical sites can now begin dosing eligible patients in a phase 2b study in localized prostate cancer Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐